Quantitatlve contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes

Drug Metabolism and Disposition

Volumn 32, Issue 4, 2004, Pages 447-454

  Lalovic, Bojan ^a,b   Phillips, Brian ^b   Risler, Linda L ^b   Howald, William ^a   Shen, Danny D ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A5; KETOCONAZOLE; MORPHINE DERIVATIVE; N DEMETHYLASE; NOROXYCODONE; O DEMETHYLASE; OXYCODONE; OXYMORPHONE; QUINIDINE; UNCLASSIFIED DRUG; COMPLEMENTARY DNA; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450; MORPHINAN DERIVATIVE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; DEMETHYLATION; DRUG OXIDATION; ENZYME ACTIVITY; FIRST PASS EFFECT; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM; LIVER MICROSOME METABOLISM; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REACTION ANALYSIS; BIOTRANSFORMATION; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; INTESTINE; KINETICS; LIVER MICROSOME; METABOLIC CLEARANCE RATE; METABOLISM; METHYLATION; MICROSOME; PROTEIN BINDING; ULTRASTRUCTURE;

STAPHYLOCOCCUS PHAGE 3A;

ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; HUMANS; INTESTINES; KETOCONAZOLE; KINETICS; METABOLIC CLEARANCE RATE; METHYLATION; MICROSOMES; MICROSOMES, LIVER; MOLECULAR STRUCTURE; MORPHINANS; OXIDOREDUCTASES, N-DEMETHYLATING; OXYCODONE; OXYMORPHONE; PROTEIN BINDING; QUINIDINE;

EID: 1842536807     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.32.4.447     Document Type: Article

References (39)

1. Caraco Y, Sheller J, and Wood AJ (1996a) Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. J Pharmacol Exp Ther 278:1165-1174.
2. Caraco Y, Tateishi T, Guengerich FP, and Wood AJ (1996b) Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity. Drug Metab Dispos 24:761-764.
3. Chen ZR, Irvine RJ, Somogyi AA, and Bochner F (1991) Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 48:2165-2171.
4. Childers SR, Creese I, Snowman AM, and Snyder SH (1979) Opiate receptor binding affected differentially by opiates and opioid peptides. Eur J Pharmacol 55:11-18.
5. Cleary J, Mikus G, Somogyi A, and Bochner F (1994) The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model. J Pharmacol Exp Ther 271:1528-1534.
6. Curtis GB, Johnson GH, Clark P, Taylor R, Brown J, O'Callaghan R, Shi M, and Lacouture PG (1999) Relative potency of controlled-release oxycodone and controlled-release morphine in a postoperative pain model. Eur J Clin Pharmacol 55:425-429.
7. Dayer P, Desmeules J, Leemann T, and Striberni R (1988) Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P450 dbl/bufI). Biochem Biophys Res Commun 152:411-416.
8. Dayer P, Leemann T, and Striberni R (1989) Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 dbl activity. Clin Pharmacol Ther 45:34-40.
9. De Conno F, Ripamonti C, Sbanotto A, Barletta L, Zecca E, Martini C, and Ventafridda V (1991) A clinical study on the use of codeine, oxycodone, dextropropoxyphene, buprenorphine and pentazocine in cancer pain. J Pain Symptom Manage 6:423-427.
10. Gibbs MA, Thummel KE, Shen DD, and Kunze KL (1999) Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 27:180-187.
11. Glare PA and Walsh TD (1993) Dose-ranging study of oxycodone for chronic pain in advanced cancer. J Clin Oncol 11:973-978.
12. Gorski JC, Jones DR, Wrighton SA, and Hall SD (1994) Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 48:173-182.
13. Heiskanen T, Olkkola KT, and Kalso E (1998) Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 64:603-611.
14. Ishida T, Oguri K, and Yoshimura H (1979) Isolation and identification of urinary metabolites of oxycodone in rabbits. Drug Metab Dispos 7:162-165.
15. Ishida T, Oguri K, and Yoshimura H (1982) Determination of oxycodone metabolites in urines and feces of several mammalian species. J Pharmacobiodyn 5:521-525.
16. Kaiko RF, Benziger DP, Fitzmartin RD, Burke BE, Reder RF, and Goldenheim PD (1996) Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 59:52-61.
17. Kaplan HL, Busto UE, Baylon GJ, Cheung SW, Otton SV, Somer G, and Sellers EM (1997) Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. J Pharmacol Exp Ther 281:103-108.
18. Kirvela M, Lindgren L, Seppala T, and Olkkola KT (1996) The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 8:13-18.
19. Kronbach T, Mathys D, Gut J, Catin T, and Meyer UA (1987) High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem 162:24-32.
20. Lamba JK, Lin YS, Schuetz EG, and Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294.
21. Leow KP and Smith MT (1994) The antinociceptive potencies of oxycodone, noroxycodone and morphine after intracerebroventricular administration to rats. Life Sci 54:1229-1236.
22. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, and Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162-172.
23. Madani S, Paine MF, Lewis L, Thummel KE, and Shen DD (1999) Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines. Pharm Res (NY) 16:1199-1205.
24. Melmon KL, Hoffman BB, and Niemberg DW (2000) Melmon and Morelli's Clinical Pharmacology. McGraw-Hill, New York.
25. Nuutinen LS, Wuolijoki E, and Pentikainen IT (1986) Diclofenac and oxycodone in treatment of postoperative pain: a double-blind trial. Acta Anaesthesiol Scand 30:620-624.
26. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
27. Otton SV, Wu D, Joffe RT, Cheung SW, and Sellers EM (1993) Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 53:401-409.
28. Parris WC, Johnson BW Jr, Croghan MK, Moore MR, Khojasteh A, Reder RF, Kaiko RF, and Buckley BJ (1998) The use of controlled-release oxycodone for the treatment of chronic cancer pain: a randomized, double-blind study. J Pain Symptom Manage 16:205-211.
29. Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF, Elbaek K, and Sindrup SH (1996) Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 51:289-295.
30. Poyhia R, Olkkola KT, Seppala T, and Kalso E (1991) The pharmacokinetics of oxycodone after intravenous injection in adults. Br J Clin Pharmacol 32:516-518.
31. Poyhia R, Seppala T, Olkkola KT, and Kalso E (1992) The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 33:617-621.
32. Segel I (1975) Enzyme Kinetics, John Wiley & Sons, New York.
33. Silvasti M, Rosenberg P, Seppala T, Svartling N, and Pitkanen M (1998) Comparison of analgesic efficacy of oxycodone and morphine in postoperative intravenous patient-controlled analgesia. Acta Anaesthesiol Scand 42:576-580.
34. Sindrup SH and Jensen TS (1999) Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 83:389-400.
35. Somogyi AA (1999) Characterization of cytochrome P450 informs involved in oxycodone oxidative metabolism in humans, in 9th World Congress on Pain; 1999 Aug 23-27: Vienna, Austria.
36. Tomkins DM, Otton SV, Joharchi N, Li NY, Balster RF, Tyndale RF, and Sellers EM (1997) Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats. J Pharmacol Exp Ther 280:1374-1382.
37. Watson CP and Babul N (1998) Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 50:1837-1841.
38. Weinstein SH and Gaylord JC (1979) Determination of oxycodone in plasma and identification of a major metabolite. J Pharm Sci 68:527-528.
39. Wilder-Smith CH, Hufschmid E, and Thormann W (1998) The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor metabolizers. Br J Clin Pharmacol 45:575-581.